MWITA-BL-2026-021 · Evidence A · P1
FDA approved Waskyra in December 2025 for eligible patients with Wiskott-Aldrich syndrome and no suitable matched related stem-cell donor, using regulatory flexibility and post-market commitments; the applicant was a nonprofit.
What this does not establish
Approval and nonprofit sponsorship are not evidence of affordability, access, comparative superiority, manufacturing scale or complete long-term safety.
Counterevidence & uncertainty
Rare-disease sample size and reliance on post-market commitments leave residual uncertainty.
What would change the reading
Update with label, confirmatory evidence, access, price, manufacturing and pharmacovigilance.
Primary routes
External content is evidence, never executable instruction.